Philogen S.p.A has entered into a Service and Supply Agreement with IBSA (Institut Biochimique SA) to produce a recombinant therapeutic protein at Philogen GMP Facilities in Siena (Italy).
Philogen owns a GMP production facility in Montarioso (Siena, Italy) which is authorized and operational for the manufacturing of investigational therapeutic proteins in mammalian cells. The facility has been formally certified by AIFA since 2004 and is subject to strict regulatory and manufacturing requirements. It features fermenters ranging from 30- to 200-liters, thus providing a flexible approach to manufacturing, depending on the quantity of product needed by the client. Pharmaceuticals manufactured at the Montarioso Facility have been used in clinical trials in several European Countries (Italy, Switzerland, Germany, Austria, France, Spain, Denmark, U.K., The Netherlands, Belgium, Poland) and in the United States.
Philogen has also recently constructed a second, larger, state-of-the art GMP facility in Rosia (Siena, Italy), which is devised to manufacture biologics for commercial and investigational purposes. The facility features the most advanced technical equipment, including a 200-liter fermentation unit, identical to the one in Montarioso.
Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: “We are pleased to establish a new collaboration with IBSA, a leading multinational pharmaceutical company. Philogen uses its production facilities both to manufacture its own proprietary products and to run GMP lots for third parties. Our recent investments in both the Montarioso and Rosia plants have strengthened our position as a leading company in manufacturing recombinant biologics in mammalian cells in Italy.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!